Acceptability of Expanded Newborn Screening to Parents in France With or Without Genetics in the First Line
NCT ID: NCT06111456
Last Updated: 2023-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1585 participants
OBSERVATIONAL
2022-09-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The SeDeN-p3 Study focuses on the opinions of parents. It aims to analyze the perception of parents in different situations: birth, early childhood, child screened in the framework of the national neonatal screening program, etc. The objective of this part is to study the understanding and expectations of parents in France regarding the extension of newborn screening as well as their preferences regarding its conditions (information, types of pathologies, screening methods, etc.).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Technical Feasibility of the cfDNA Test for Non-invasive Cytogenetic Analysis of Early Miscarriages Versus the Gold Standard Microarray
NCT05900076
Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants
NCT02964793
Non-invasive Screening of Fetal Trisomy 21 by Digital PCR
NCT03687866
Validate Non-invasive Prenatal Tests for the Detection of Chromosomal Abnormalities
NCT05618431
Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness
NCT04905537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Population 1Q
Parents or co-parents of a newborn child.
Questionnaire
Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
Interview
Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
Population 2
Parents or co-parents whose youngest child is 1 week to 3 years old.
Questionnaire
Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
Population 3
Parents or co-parents whose child had a suspicious newborn screening result that was confirmed at the diagnosis phase (except hearing).
Interview
Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
Population 4
Parents or co-parents whose child was diagnosed later based on clinical signs for diseases not included in the list of diseases screening in French newborn screening, but included in the list of diseases screened in newborn screening in other countries.
Interview
Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire
Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
Interview
Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be a parent or co-parent
* Age of parent:
* woman between 18 and 50 years
* man between 18 and 60 years
* Live in metropolitan France
* Have received information about the SeDeN-p3 Study
* Understand the purpose of the SeDeN-p3 Study
Self-administered questionnaire:
* Be able to read and answer a self-administered questionnaire in French
* Population 1Q:
* Have a child less than a week old
* Have just giver birth in 1 of the partner maternity hospitals during the survey period
* Population 2:
* Parent or co-parent whose youngest child is between 1 week and 3 years old
* Be part of the panel of the selected survey-sample firm
Semi-structured interviews
* Can converse fluently in French
* Accept to conduct a recorded interview
* Population 1E (sub-population of Population 1Q)
* Have completed the entire questionnaire
* Population 3
* Have a child under 5 years old (inclusive) with 1 of the following diseases :
* Phenylketonuria
* Congenital hypothyroidism
* Congenital adrenal hyperplasia
* Cystic fibrosis
* Sickle cell disease
* hearing loss
* MCAD deficiency
* glutaric aciduria type -1
* isovaleric academia
* LCHAD deficiency
* carnitine deficiency
* homocystinuria
* leukinosis
* tyrosinemia type 1
* Population 4
* Have a child under 17 years old (inclusive), with 1 of following diseases:
* Citrullinemia type I
* Ornithine Transcarbamylase Deficiency
* Methylmalonic acidaemia
* Very long-chain acyl-CoA dehydrogenase deficiency
* Carnitine palmitoyl transferase 1 deficiency
* Carnitine palmitoyl transferase 2 deficiency
* Glutaric acidaemia type II
* Galactosaemia
* Biotinidase deficiency
* Pompe Disease
* Mucopolysaccharidosis Type 1
* Glucose-6-phophate dehydrogenase deficiency
* X-linked Adrenoleukodystrophy
* Spinal muscular atrophy linked to SMN1
* S, beta-thalassemia
Exclusion Criteria
* Not speak and/or understand French
* Refuse to participate in the SeDeN-p3 Study
* Be under judicial protection (tutelle, curatelle, habilitation familiale et sauvegarde de justice)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Antoine Beclere - Aphp
Clamart, , France
Chu Dijon Bourgogne
Dijon, , France
Hôpital Necker - Enfants Malades
Paris, , France
Groupe Hospitalier de La Haute-Saône
Vesoul, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OLIVIER-FAIVRE 2021-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.